(Q35992891)

11 August 2017

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients (English)

1 reference

11 August 2017

Nicolini A

1

1 reference

11 August 2017

Colombini C

2

1 reference

11 August 2017

Luciani L

3

1 reference

11 August 2017

Carpi A

4

1 reference

11 August 2017

Giuliani L

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 July 1991

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

64

1 reference

11 August 2017

1

1 reference

11 August 2017

154-158

1 reference

Ability of CEA blood levels to reflect tumour burden: a study in a human xenograft model

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977334

Tumor markers for breast carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977334

Isolation from patients with breast cancer of antibodies specific for antigens associated with breast cancer and other malignant diseases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977334

Serum antibody in patients with mammary disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977334

A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977334

Carcinoembryonic antigen and breast carcinoma antigen (CA 15.3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast

23 September 2018

1 reference

12 December 2020

Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients

1 reference

12 December 2020

Circulating CA 15.3 levels in breast cancer. Our present experience

1 reference

12 December 2020

CA 15.3 as a tumour marker in breast cancer

1 reference

12 December 2020

Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials

1 reference

12 December 2020

Recovery of immunologically reactive antibodies and antigens from breast cancer immune complexes by preparative isoelectric focusing

1 reference

12 December 2020

Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer)

1 reference

12 December 2020

Treatment of primary breast cancer with chemotherapy and tamoxifen

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1991.260

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

1854615

1 reference